Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study

Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (date from preprint)
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 79% Improvement Relative Risk Hospitalization 82% HCQ for COVID-19  Derwand et al.  EARLY TREATMENT Is early treatment with HCQ + AZ and zinc beneficial for COVID-19? Retrospective 518 patients in the USA Lower hospitalization with HCQ + AZ and zinc (p=0.001) c19hcq.org Derwand et al., Int. J. Antimicrobial .., Jul 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. No cardiac side effects. Retrospective 518 patients (141 treated, 377 control).
Study covers zinc and HCQ.
risk of death, 79.4% lower, RR 0.21, p = 0.12, treatment 1 of 141 (0.7%), control 13 of 377 (3.4%), NNT 37, odds ratio converted to relative risk.
risk of hospitalization, 81.6% lower, RR 0.18, p < 0.001, treatment 4 of 141 (2.8%), control 58 of 377 (15.4%), NNT 8.0, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Derwand et al., 3 Jul 2020, retrospective, USA, peer-reviewed, 3 authors, average treatment delay 4.0 days, dosage 200mg bid days 1-5, this trial uses multiple treatments in the treatment arm (combined with AZ and zinc) - results of individual treatments may vary.
This PaperHCQAll
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
Roland Derwand, Martin Scholz, Vladimir Zelenko
International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214
The aim of this study was to describe the outcomes of patients with coronavirus disease 2019 in the outpatient setting after early treatment with zinc, low-dose hydroxychloroquine and azithromycin (triple therapy) dependent on risk stratification. This was a retrospective case series study in the general practice setting. A total of 141 COVID-19 patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the year 2020 were included. The main outcome measures were risk-stratified treatment decision and rates of hospitalisation and all-cause death. A median of 4 days [interquartile range (IQR) 3-6 days; available for n = 66/141 patients] after the onset of symptoms, 141 patients (median age 58 years, IQR 40-67 years; 73.0% male) received a prescription for triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients in the same community were used as untreated controls. Of 141 treated patients, 4 (2.8%) were hospitalised, which was significantly fewer ( P < 0.001) compared with 58 (15.4%) of 377 untreated patients [odds ratio (OR) = 0.16, 95% confidence interval (CI) 0.06-0.5]. One patient (0.7%) in the treatment group died versus 13 patients (3.4%) in the untreated group (OR = 0.2, 95% CI 0.03-1.5; P = 0.12). No cardiac side effects were observed. Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset using triple therapy, including the combination of zinc with low-dose hydroxychloroquine, was associated with significantly fewer hospitalisations.
Competing interests RD is/was at the time of writing an employee of Alexion Pharma Germany GmbH, and his engagement and contribution to this study and publication was private and independent from his employer; MS is/was at the time of writing External Senior Advisor for the company LEUKOCARE (Munich, Germany) and is/was Manging Director at Starts-and -Ups Consulting (Frankfurt, Germany); VZ is/was a general practitioner in New York State (USA). Ethical approval This study was approved by the Western Institutional Review Board and was exempt under 45 CFR § 46.104(d)(4). Ref. Number: D4-Excemption-Zelenko (06-16-2020).
References
Anderson, Roussel, Zouari, Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus, J Am Coll Nutr, doi:10.1080/07315724.2001.10719034
Andreani, Bideau, Duflot, In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog, doi:10.1016/j.micpath.2020.104228
Atri, Siddiqi, Lang, COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies, JACC Basic Transl Sci, doi:10.1016/j.jacbts.2020.04.002
Boulware, Pullen, Bangdiwala, A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19, N Engl J Med, doi:10.1056/NEJMoa2016638
Braun, Rosenfeldt, Pharmaco-nutrient interactions-a systematic review of zinc and antihypertensive therapy, Int J Clin Pract, doi:10.1111/ijcp.12040
Carlucci, Ahuja, Petrilli, Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients, medRxiv, doi:10.1101/2020.05.02.20080036
Chen, Liu, Liu, A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19, Zhejiang Da Xue Xue Bao Yi Xue Ban, doi:10.3785/j.issn.1008-9292.2020.03.03
Chen, Wu, Chen, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ, doi:10.1136/bmj.m1091
Coutard, Valle, De Lamballerie, The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antiviral Res, doi:10.1016/j.antiviral.2020.104742
Derwand, Scholz, Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?, Med Hypotheses, doi:10.1016/j.mehy.2020.109815
Ervin, Kennedy-Stephenson, Mineral intakes of elderly adult supplement and non-supplement users in the third National Health and Nutrition Examination Survey, J Nutr, doi:10.1093/jn/132.11.3422
Esper, Da Silva, Oikawa, Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
Fry, Goswami, Nahar, Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial, Lancet Infect Dis, doi:10.1016/s1473-3099(13)70267-6
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Ghaly, Knezevic, What happened to 'patient first' and 'do no harm' medical principles?, Surg Neurol Int, doi:10.4103/sni.sni_447_17
Giacomelli, Pezzati, Conti, Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study, Clin Infect Dis, doi:10.1093/cid/ciaa330
Gonçalves, Bertrand, Ke, Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load, medRxiv, doi:10.1101/2020.04.04.20047886
Gordon, Amissah-Arthur, Gayed, The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults, Rheumatology, doi:10.1093/rheumatology/kex286
Gupta, Real-world clinical effectiveness and tolerability of hydroxychloroquine 400 mg in uncontrolled type 2 diabetes subjects who are not willing to initiate insulin therapy (HYQ-Real-World Study), Curr Diabetes Rev, doi:10.2174/1573399815666190425182008
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/s0140-6736(20)30183-5
Johnson, Rigge, Culliford, Primary care risk stratification in COPD using routinely collected data: a secondary data analysis, NPJ Prim Care Respir Med, doi:10.1038/s41533-019-0154-6
Kane, Hydroxychloroquine sulfate. Drug usage statistics
Kim, Ko, Kim, Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea, J Korean Med Sci, doi:10.3346/jkms.2020.35.e86
Lane, Weaver, Kostka, Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study, medRxiv, doi:10.1101/2020.04.08.20054551
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Lovato, De Filippis, Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms, Ear Nose Throat J, doi:10.1177/0145561320920762
Mahevas, Tran, Roumier, No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv, doi:10.1101/2020.04.10.20060699
Mehra, Ruschitzka, Patel, Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet, doi:10.1016/S0140-6736(20)31324-6
Meo, Klonoff, Akram, Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev_202004_21038
Mercer, Rekedal, Garg, Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals, Arthritis Res Ther, doi:10.1186/ar3868
Millet, Whittaker, Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein, Proc Natl Acad Sci U S A, doi:10.1073/pnas.1407087111
Million, Gautret, Colson, Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world, New Microbes New Infect, doi:10.1016/j.nmni.2020.100709
Million, Lagier, Gautret, Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA, doi:10.1001/jama.2020.4683
Pan, Zhang, Yang, Viral load of SARS-CoV-2 in clinical samples, Lancet Infect Dis, doi:10.1016/s1473-3099(20)30113-4
Pareek, Chandurkar, Thomas, Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone, Curr Med Res Opin, doi:10.1185/03007995.2014.909393
Podsiadlo, Komiyama, Fuller, Furin inhibition by compounds of copper and zinc, J Biol Chem, doi:10.1074/jbc.M400338200
Prasad, Beck, Bao, Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress, Am J Clin Nutr, doi:10.1093/ajcn/85.3.837
Prieto-Alhambra, Ballo, Coma-Redon, Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases, medRxiv, doi:10.1101/2020.05.04.20090050
Read, Obeid, Ahlenstiel, The role of zinc in antiviral immunity, Adv Nutr, doi:10.1093/advances/nmz013
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA, doi:10.1001/jama.2020.6775
Risch, Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped-up immediately as key to the pandemic crisis, Am J Epidemiol, doi:10.1093/aje/kwaa093
Ronco, Reis, Husain-Syed, Management of acute kidney injury in patients with COVID-19, Lancet Respir Med, doi:10.1016/s2213-2600(20)30229-0
Schlagenhauf, Grobusch, Maier, Repurposing antimalarials and other drugs for COVID-19, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101658
Shiryaev, Remacle, Ratnikov, Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens, J Biol Chem, doi:10.1074/jbc.M703847200
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal, J Heart Lung Transplant, doi:10.1016/j.healun.2020.03.012
Siemieniuk, Bartoszko, Ge, Drug treatments for COVID-19: living systematic review and network meta-analysis, BMJ, doi:10.1136/bmj.m2980
Stawowy, Kallisch, Pereira Stawowy, Immunohistochemical localization of subtilisin/kexin-like proprotein convertases in human atherosclerosis, Virchows Arch, doi:10.1007/s00428-004-1198-7
Talan, Guterman, Overturf, Analysis of emergency department management of suspected bacterial meningitis, Ann Emerg Med, doi:10.1016/s0196-0644(89)80213-6
Tang, Cao, Han, Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial, medRxiv, doi:10.1101/2020.04.10.20060558
Tett, Cutler, Day, Bioavailability of hydroxychloroquine tablets in healthy volunteers, Br J Clin Pharmacol, doi:10.1111/j.1365-2125.1989.tb03439.x
Van Den Akker, Buntinx, Metsemakers, Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases, J Clin Epidemiol, doi:10.1016/s0895-4356(97)00306-5
Velthuis, Van Den Worm, Sims, Zn 2 + inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, PLoS Pathog, doi:10.1371/journal.ppat.1001176
Wallace, The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review, Lupus
Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Wu, Wu, Liu, The SARS-CoV-2 outbreak: what we know, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.004
Xue, Moyer, Peng, Chloroquine is a zinc ionophore, PLoS One, doi:10.1371/journal.pone.0109180
Yang, Shen, Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19, Int J Biol Sci, doi:10.7150/ijbs.45498
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Yu, Li, Chen, Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19, Sci China Life Sci, doi:10.1007/s11427-020-1732-2
Zarychanski, Stuart, Kumar, Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection, CMAJ, doi:10.1503/cmaj.091884
Zou, Ruan, Huang, SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N Engl J Med, doi:10.1056/NEJMc2001737
{ 'indexed': {'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T07:06:16Z', 'timestamp': 1709276776168}, 'reference-count': 69, 'publisher': 'Elsevier BV', 'issue': '6', 'license': [ { 'start': { 'date-parts': [[2020, 12, 1]], 'date-time': '2020-12-01T00:00:00Z', 'timestamp': 1606780800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2020, 10, 25]], 'date-time': '2020-10-25T00:00:00Z', 'timestamp': 1603584000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 12]]}, 'DOI': '10.1016/j.ijantimicag.2020.106214', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 10, 26]], 'date-time': '2020-10-26T16:42:42Z', 'timestamp': 1603730562000}, 'page': '106214', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 79, 'title': 'COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine ' 'and azithromycin: a retrospective case series study', 'prefix': '10.1016', 'volume': '56', 'author': [ {'given': 'Roland', 'family': 'Derwand', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7009-9988', 'authenticated-orcid': False, 'given': 'Martin', 'family': 'Scholz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vladimir', 'family': 'Zelenko', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijantimicag.2020.106214_bib0001', 'doi-asserted-by': 'crossref', 'first-page': '44', 'DOI': '10.1016/j.ijid.2020.03.004', 'article-title': 'The SARS-CoV-2 outbreak: what we know', 'volume': '94', 'author': 'Wu', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '518', 'DOI': '10.1016/j.jacbts.2020.04.002', 'article-title': 'COVID-19 for the cardiologist: a current review of the virology, ' 'clinical epidemiology, cardiac and other clinical manifestations and ' 'potential therapeutic strategies', 'volume': '5', 'author': 'Atri', 'year': '2020', 'journal-title': 'JACC Basic Transl Sci'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0003', 'article-title': 'Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient ' 'cases', 'volume': '8', 'author': 'Prieto-Alhambra', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '856', 'DOI': '10.1016/S0196-0644(89)80213-6', 'article-title': 'Analysis of emergency department management of suspected bacterial ' 'meningitis', 'volume': '18', 'author': 'Talan', 'year': '1989', 'journal-title': 'Ann Emerg Med'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0005', 'article-title': 'Timing of antiviral treatment initiation is critical to reduce ' 'SARS-CoV-2 viral load', 'author': 'Gonçalves', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '405', 'DOI': '10.1016/j.healun.2020.03.012', 'article-title': 'COVID-19 illness in native and immunosuppressed states: a ' 'clinical-therapeutic staging proposal', 'volume': '39', 'author': 'Siddiqi', 'year': '2020', 'journal-title': 'J Heart Lung Transplant'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0007', 'doi-asserted-by': 'crossref', 'first-page': '109', 'DOI': '10.1016/S1473-3099(13)70267-6', 'article-title': 'Efficacy of oseltamivir treatment started within 5 days of symptom ' 'onset to reduce influenza illness duration and virus shedding in an ' 'urban setting in Bangladesh: a randomised placebo-controlled trial', 'volume': '14', 'author': 'Fry', 'year': '2014', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0008', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101658', 'article-title': 'Repurposing antimalarials and other drugs for COVID-19', 'volume': '34', 'author': 'Schlagenhauf', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'issue': 'Suppl 1', 'key': '10.1016/j.ijantimicag.2020.106214_bib0009', 'doi-asserted-by': 'crossref', 'first-page': 'S59', 'DOI': '10.1177/0961203396005001131', 'article-title': 'The use of chloroquine and hydroxychloroquine for non-infectious ' 'conditions other than rheumatoid arthritis or lupus: a critical review', 'volume': '5', 'author': 'Wallace', 'year': '1996', 'journal-title': 'Lupus'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0010', 'doi-asserted-by': 'crossref', 'first-page': 'e1', 'DOI': '10.1093/rheumatology/kex286', 'article-title': 'The British Society for Rheumatology guideline for the management of ' 'systemic lupus erythematosus in adults', 'volume': '57', 'author': 'Gordon', 'year': '2018', 'journal-title': 'Rheumatology (Oxford)'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0011', 'series-title': 'Model list of essential medicines', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0012', 'unstructured': 'Kane S.P.Hydroxychloroquine sulfate. Drug usage statistics, United ' 'States, 2007–2017. ClinCalc DrugStats Database, Version ' '20.1.https://clincalc.com/DrugStats/Drugs/HydroxychloroquineSulfate ' '[accessed 23 May 2020].'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0013', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial', 'volume': '56', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0014', 'article-title': 'Hydroxychloroquine in patients mainly with mild to moderate COVID-19: ' 'an open-label, randomized, controlled trial', 'author': 'Tang', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0015', 'first-page': '215', 'article-title': 'A pilot study of hydroxychloroquine in treatment of patients with ' 'moderate COVID-19', 'volume': '49', 'author': 'Chen', 'year': '2020', 'journal-title': 'Zhejiang Da Xue Xue Bao Yi Xue Ban'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0016', 'article-title': 'No evidence of clinical efficacy of hydroxychloroquine in patients ' 'hospitalized for COVID-19 infection with oxygen requirement: results of ' 'a study using routinely collected data to emulate a target trial', 'author': 'Mahevas', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0017', 'doi-asserted-by': 'crossref', 'first-page': '1820', 'DOI': '10.1016/S0140-6736(20)31324-6', 'article-title': 'Retraction—Hydroxychloroquine or chloroquine with or without a ' 'macrolide for treatment of COVID-19: a multinational registry analysis', 'volume': '395', 'author': 'Mehra', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0018', 'doi-asserted-by': 'crossref', 'first-page': 'E102', 'DOI': '10.1016/S0140-6736(20)31290-3', 'article-title': 'Expression of concern: Hydroxychloroquine or chloroquine with or ' 'without a macrolide for treatment of COVID-19: a multinational registry ' 'analysis', 'volume': '395', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0019', 'doi-asserted-by': 'crossref', 'first-page': '1724', 'DOI': '10.7150/ijbs.45498', 'article-title': 'Targeting the endocytic pathway and autophagy process as a novel ' 'therapeutic strategy in COVID-19', 'volume': '16', 'author': 'Yang', 'year': '2020', 'journal-title': 'Int J Biol Sci'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0020', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0109180', 'article-title': 'Chloroquine is a zinc ionophore', 'volume': '9', 'author': 'Xue', 'year': '2014', 'journal-title': 'PLoS One'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0021', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.ppat.1001176', 'article-title': 'Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in ' 'vitro and zinc ionophores block the replication of these viruses in ' 'cell culture', 'volume': '6', 'author': 'te Velthuis', 'year': '2010', 'journal-title': 'PLoS Pathog'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0022', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.mehy.2020.109815', 'article-title': 'Does zinc supplementation enhance the clinical efficacy of ' "chloroquine/hydroxychloroquine to win today's battle against COVID-19?", 'volume': '142', 'author': 'Derwand', 'year': '2020', 'journal-title': 'Med Hypotheses'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0023', 'article-title': 'Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and ' 'azithromycin alone: outcomes in hospitalized COVID-19 patients', 'author': 'Carlucci', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0024', 'doi-asserted-by': 'crossref', 'first-page': 'm2980', 'DOI': '10.1136/bmj.m2980', 'article-title': 'Drug treatments for COVID-19: living systematic review and network ' 'meta-analysis', 'volume': '370', 'author': 'Siemieniuk', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0025', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.nmni.2020.100709', 'article-title': 'Clinical efficacy of chloroquine derivatives in COVID-19 infection: ' 'comparative meta-analysis between the big data and the real world', 'volume': '38', 'author': 'Million', 'year': '2020', 'journal-title': 'New Microbes New Infect'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0026', 'doi-asserted-by': 'crossref', 'first-page': '517', 'DOI': '10.1056/NEJMoa2016638', 'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis ' 'for COVID-19', 'volume': '383', 'author': 'Boulware', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0027', 'doi-asserted-by': 'crossref', 'first-page': '411', 'DOI': '10.1016/S1473-3099(20)30113-4', 'article-title': 'Viral load of SARS-CoV-2 in clinical samples', 'volume': '20', 'author': 'Pan', 'year': '2020', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0028', 'doi-asserted-by': 'crossref', 'first-page': 'e86', 'DOI': '10.3346/jkms.2020.35.e86', 'article-title': 'Viral load kinetics of SARS-CoV-2 infection in first two patients in ' 'Korea', 'volume': '35', 'author': 'Kim', 'year': '2020', 'journal-title': 'J Korean Med Sci'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0029', 'doi-asserted-by': 'crossref', 'first-page': '1177', 'DOI': '10.1056/NEJMc2001737', 'article-title': 'SARS-CoV-2 viral load in upper respiratory specimens of infected ' 'patients', 'volume': '382', 'author': 'Zou', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0030', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'volume': '395', 'author': 'Huang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0031', 'doi-asserted-by': 'crossref', 'first-page': '1061', 'DOI': '10.1001/jama.2020.1585', 'article-title': 'Clinical characteristics of 138 hospitalized patients with 2019 novel ' 'coronavirus-infected pneumonia in Wuhan, China', 'volume': '323', 'author': 'Wang', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0032', 'doi-asserted-by': 'crossref', 'first-page': '257', 'DOI': '10.1503/cmaj.091884', 'article-title': 'Correlates of severe disease in patients with 2009 pandemic influenza ' '(H1N1) virus infection', 'volume': '182', 'author': 'Zarychanski', 'year': '2010', 'journal-title': 'CMAJ'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0033', 'series-title': 'Influenza (flu). For clinicians: antiviral medication', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0034', 'series-title': 'Managing people at high risk for severe varicella', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0035', 'series-title': 'Empirical treatment with hydroxychloroquine and azithromycin for ' 'suspected cases of COVID-19 followed-up by telemedicine', 'author': 'Esper', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0036', 'doi-asserted-by': 'crossref', 'first-page': '42', 'DOI': '10.1038/s41533-019-0154-6', 'article-title': 'Primary care risk stratification in COPD using routinely collected ' 'data: a secondary data analysis', 'volume': '29', 'author': 'Johnson', 'year': '2019', 'journal-title': 'NPJ Prim Care Respir Med'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0037', 'series-title': 'People at increased risk and other people who need to take extra ' 'precautions', 'year': '2020'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0038', 'doi-asserted-by': 'crossref', 'first-page': '367', 'DOI': '10.1016/S0895-4356(97)00306-5', 'article-title': 'Multimorbidity in general practice: prevalence, incidence, and ' 'determinants of co-occurring chronic and recurrent diseases', 'volume': '51', 'author': 'van den Akker', 'year': '1998', 'journal-title': 'J Clin Epidemiol'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0039', 'first-page': '1775', 'article-title': 'Case-fatality rate and characteristics of patients dying in relation to ' 'COVID-19 in Italy', 'volume': '323', 'author': 'Onder', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0040', 'doi-asserted-by': 'crossref', 'first-page': '176', 'DOI': '10.4103/sni.sni_447_17', 'article-title': 'What happened to ‘patient first’ and ‘do no harm’ medical principles?', 'volume': '9', 'author': 'Ghaly', 'year': '2018', 'journal-title': 'Surg Neurol Int'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0041', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting SARS-CoV-2 infection in vitro', 'volume': '6', 'author': 'Liu', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0042', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'volume': '71', 'author': 'Yao', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0043', 'first-page': '4539', 'article-title': 'Efficacy of chloroquine and hydroxychloroquine in the treatment of ' 'COVID-19', 'volume': '24', 'author': 'Meo', 'year': '2020', 'journal-title': 'Eur Rev Med Pharmacol Sci'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0044', 'doi-asserted-by': 'crossref', 'first-page': '771', 'DOI': '10.1111/j.1365-2125.1989.tb03439.x', 'article-title': 'Bioavailability of hydroxychloroquine tablets in healthy volunteers', 'volume': '27', 'author': 'Tett', 'year': '1989', 'journal-title': 'Br J Clin Pharmacol'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0045', 'doi-asserted-by': 'crossref', 'first-page': '837', 'DOI': '10.1093/ajcn/85.3.837', 'article-title': 'Zinc supplementation decreases incidence of infections in the elderly: ' 'effect of zinc on generation of cytokines and oxidative stress', 'volume': '85', 'author': 'Prasad', 'year': '2007', 'journal-title': 'Am J Clin Nutr'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0046', 'doi-asserted-by': 'crossref', 'first-page': '696', 'DOI': '10.1093/advances/nmz013', 'article-title': 'The role of zinc in antiviral immunity', 'volume': '10', 'author': 'Read', 'year': '2019', 'journal-title': 'Adv Nutr'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0047', 'doi-asserted-by': 'crossref', 'first-page': '36219', 'DOI': '10.1074/jbc.M400338200', 'article-title': 'Furin inhibition by compounds of copper and zinc', 'volume': '279', 'author': 'Podsiadlo', 'year': '2004', 'journal-title': 'J Biol Chem'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0048', 'doi-asserted-by': 'crossref', 'first-page': '351', 'DOI': '10.1007/s00428-004-1198-7', 'article-title': 'Immunohistochemical localization of subtilisin/kexin-like proprotein ' 'convertases in human atherosclerosis', 'volume': '446', 'author': 'Stawowy', 'year': '2005', 'journal-title': 'Virchows Arch'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0049', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104742', 'article-title': 'The spike glycoprotein of the new coronavirus 2019-nCoV contains a ' 'furin-like cleavage site absent in CoV of the same clade', 'volume': '176', 'author': 'Coutard', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0050', 'doi-asserted-by': 'crossref', 'first-page': '15214', 'DOI': '10.1073/pnas.1407087111', 'article-title': 'Host cell entry of Middle East respiratory syndrome coronavirus after ' 'two-step, furin-mediated activation of the spike protein', 'volume': '111', 'author': 'Millet', 'year': '2014', 'journal-title': 'Proc Natl Acad Sci U S A'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0051', 'doi-asserted-by': 'crossref', 'first-page': '20847', 'DOI': '10.1074/jbc.M703847200', 'article-title': 'Targeting host cell furin proprotein convertases as a therapeutic ' 'strategy against bacterial toxins and viral pathogens', 'volume': '282', 'author': 'Shiryaev', 'year': '2007', 'journal-title': 'J Biol Chem'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0052', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.micpath.2020.104228', 'article-title': 'In vitro testing of combined hydroxychloroquine and azithromycin on ' 'SARS-CoV-2 shows synergistic effect', 'volume': '145', 'author': 'Andreani', 'year': '2020', 'journal-title': 'Microb Pathog'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0053', 'doi-asserted-by': 'crossref', 'first-page': '3422', 'DOI': '10.1093/jn/132.11.3422', 'article-title': 'Mineral intakes of elderly adult supplement and non-supplement users in ' 'the third National Health and Nutrition Examination Survey', 'volume': '132', 'author': 'Ervin', 'year': '2002', 'journal-title': 'J Nutr'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0054', 'doi-asserted-by': 'crossref', 'first-page': '212', 'DOI': '10.1080/07315724.2001.10719034', 'article-title': 'Potential antioxidant effects of zinc and chromium supplementation in ' 'people with type 2 diabetes mellitus', 'volume': '20', 'author': 'Anderson', 'year': '2001', 'journal-title': 'J Am Coll Nutr'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0055', 'doi-asserted-by': 'crossref', 'first-page': '717', 'DOI': '10.1111/ijcp.12040', 'article-title': 'Pharmaco-nutrient interactions—a systematic review of zinc and ' 'antihypertensive therapy', 'volume': '67', 'author': 'Braun', 'year': '2013', 'journal-title': 'Int J Clin Pract'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0056', 'article-title': 'Safety of hydroxychloroquine, alone and in combination with ' 'azithromycin, in light of rapid wide-spread use for COVID-19: a ' 'multinational, network cohort and self-controlled case series study', 'author': 'Lane', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0057', 'doi-asserted-by': 'crossref', 'first-page': '2052', 'DOI': '10.1001/jama.2020.6775', 'article-title': 'Presenting characteristics, comorbidities, and outcomes among 5700 ' 'patients hospitalized with COVID-19 in the New York City Area', 'volume': '323', 'author': 'Richardson', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0058', 'doi-asserted-by': 'crossref', 'first-page': '569', 'DOI': '10.1177/0145561320920762', 'article-title': 'Clinical presentation of COVID-19: a systematic review focusing on ' 'upper airway symptoms', 'volume': '99', 'author': 'Lovato', 'year': '2020', 'journal-title': 'Ear Nose Throat J'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0059', 'doi-asserted-by': 'crossref', 'first-page': 'm1091', 'DOI': '10.1136/bmj.m1091', 'article-title': 'Clinical characteristics of 113 deceased patients with coronavirus ' 'disease 2019: retrospective study', 'volume': '368', 'author': 'Chen', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0060', 'doi-asserted-by': 'crossref', 'first-page': '889', 'DOI': '10.1093/cid/ciaa330', 'article-title': 'Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a ' 'cross-sectional study', 'volume': '71', 'author': 'Giacomelli', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0061', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101738', 'article-title': 'Early treatment of COVID-19 patients with hydroxychloroquine and ' 'azithromycin: a retrospective analysis of 1061 cases in Marseille, ' 'France', 'volume': '35', 'author': 'Million', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0062', 'doi-asserted-by': 'crossref', 'first-page': '2411', 'DOI': '10.1056/NEJMoa2012410', 'article-title': 'Observational study of hydroxychloroquine in hospitalized patients with ' 'COVID-19', 'volume': '382', 'author': 'Geleris', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0063', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/aje/kwaa093', 'article-title': 'Early outpatient treatment of symptomatic, high-risk COVID-19 patients ' 'that should be ramped-up immediately as key to the pandemic crisis', 'author': 'Risch', 'year': '2020', 'journal-title': 'Am J Epidemiol'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0064', 'doi-asserted-by': 'crossref', 'first-page': '1515', 'DOI': '10.1007/s11427-020-1732-2', 'article-title': 'Low dose of hydroxychloroquine reduces fatality of critically ill ' 'patients with COVID-19', 'volume': '63', 'author': 'Yu', 'year': '2020', 'journal-title': 'Sci China Life Sci'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0065', 'doi-asserted-by': 'crossref', 'first-page': 'R135', 'DOI': '10.1186/ar3868', 'article-title': 'Hydroxychloroquine improves insulin sensitivity in obese non-diabetic ' 'individuals', 'volume': '14', 'author': 'Mercer', 'year': '2012', 'journal-title': 'Arthritis Res Ther'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0066', 'doi-asserted-by': 'crossref', 'first-page': '1257', 'DOI': '10.1185/03007995.2014.909393', 'article-title': 'Efficacy and safety of hydroxychloroquine in the treatment of type 2 ' 'diabetes mellitus: a double blind, randomized comparison with ' 'pioglitazone', 'volume': '30', 'author': 'Pareek', 'year': '2014', 'journal-title': 'Curr Med Res Opin'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0067', 'doi-asserted-by': 'crossref', 'first-page': '510', 'DOI': '10.2174/1573399815666190425182008', 'article-title': 'Real-world clinical effectiveness and tolerability of ' 'hydroxychloroquine 400 mg in uncontrolled type 2 diabetes subjects who ' 'are not willing to initiate insulin therapy (HYQ-Real-World Study)', 'volume': '15', 'author': 'Gupta', 'year': '2019', 'journal-title': 'Curr Diabetes Rev'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0068', 'doi-asserted-by': 'crossref', 'first-page': '738', 'DOI': '10.1016/S2213-2600(20)30229-0', 'article-title': 'Management of acute kidney injury in patients with COVID-19', 'volume': '8', 'author': 'Ronco', 'year': '2020', 'journal-title': 'Lancet Respir Med'}, { 'key': '10.1016/j.ijantimicag.2020.106214_bib0069', 'series-title': 'Plaquenil drug monograph', 'year': '2017'}], 'container-title': 'International Journal of Antimicrobial Agents', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857920304258?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857920304258?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 7, 3]], 'date-time': '2022-07-03T15:57:44Z', 'timestamp': 1656863864000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0924857920304258'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 12]]}, 'references-count': 69, 'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2020, 12]]}}, 'alternative-id': ['S0924857920304258'], 'URL': 'http://dx.doi.org/10.1016/j.ijantimicag.2020.106214', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.20944/preprints202007.0025.v1', 'asserted-by': 'object'}]}, 'ISSN': ['0924-8579'], 'subject': ['Pharmacology (medical)', 'Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Antimicrobial Agents', 'published': {'date-parts': [[2020, 12]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose ' 'hydroxychloroquine and azithromycin: a retrospective case series study', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Antimicrobial Agents', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijantimicag.2020.106214', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 The Author(s). Published by Elsevier Ltd.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '106214'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit